Historical Valuation
Pulse Biosciences Inc (PLSE) is now in the Overvalued zone, suggesting that its current forward PS ratio of 362.96 is considered Overvalued compared with the five-year average of -9.89. The fair price of Pulse Biosciences Inc (PLSE) is between 1.46 to 13.31 according to relative valuation methord. Compared to the current price of 14.49 USD , Pulse Biosciences Inc is Overvalued By 8.89%.
Relative Value
Fair Zone
1.46-13.31
Current Price：14.49
8.89%
Overvalued
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Pulse Biosciences Inc (PLSE) has a current Price-to-Book (P/B) ratio of 9.79. Compared to its 3-year average P/B ratio of 5.33 , the current P/B ratio is approximately 83.59% higher. Relative to its 5-year average P/B ratio of 8.33, the current P/B ratio is about 17.51% higher. Pulse Biosciences Inc (PLSE) has a Forward Free Cash Flow (FCF) yield of approximately -5.38%. Compared to its 3-year average FCF yield of -9.48%, the current FCF yield is approximately -43.31% lower. Relative to its 5-year average FCF yield of -20.73% , the current FCF yield is about -74.07% lower.
P/B
Median3y
5.33
Median5y
8.33
FCF Yield
Median3y
-9.48
Median5y
-20.73
Competitors Valuation Multiple
AI Analysis for PLSE
The average P/S ratio for PLSE competitors is 65.54, providing a benchmark for relative valuation. Pulse Biosciences Inc Corp (PLSE.O) exhibits a P/S ratio of 362.96, which is 453.83% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
AI Analysis for PLSE
1Y
3Y
5Y
Market capitalization of PLSE increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of PLSE in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is PLSE currently overvalued or undervalued?
Pulse Biosciences Inc (PLSE) is now in the Overvalued zone, suggesting that its current forward PS ratio of 362.96 is considered Overvalued compared with the five-year average of -9.89. The fair price of Pulse Biosciences Inc (PLSE) is between 1.46 to 13.31 according to relative valuation methord. Compared to the current price of 14.49 USD , Pulse Biosciences Inc is Overvalued By 8.89% .
What is Pulse Biosciences Inc (PLSE) fair value?
PLSE's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Pulse Biosciences Inc (PLSE) is between 1.46 to 13.31 according to relative valuation methord.
How does PLSE's valuation metrics compare to the industry average?
The average P/S ratio for PLSE's competitors is 65.54, providing a benchmark for relative valuation. Pulse Biosciences Inc Corp (PLSE) exhibits a P/S ratio of 362.96, which is 453.83% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for Pulse Biosciences Inc (PLSE) as of Jan 10 2026?
As of Jan 10 2026, Pulse Biosciences Inc (PLSE) has a P/B ratio of 9.79. This indicates that the market values PLSE at 9.79 times its book value.
What is the current FCF Yield for Pulse Biosciences Inc (PLSE) as of Jan 10 2026?
As of Jan 10 2026, Pulse Biosciences Inc (PLSE) has a FCF Yield of -5.38%. This means that for every dollar of Pulse Biosciences Inc’s market capitalization, the company generates -5.38 cents in free cash flow.
What is the current Forward P/E ratio for Pulse Biosciences Inc (PLSE) as of Jan 10 2026?
As of Jan 10 2026, Pulse Biosciences Inc (PLSE) has a Forward P/E ratio of -8.64. This means the market is willing to pay $-8.64 for every dollar of Pulse Biosciences Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Pulse Biosciences Inc (PLSE) as of Jan 10 2026?
As of Jan 10 2026, Pulse Biosciences Inc (PLSE) has a Forward P/S ratio of 362.96. This means the market is valuing PLSE at $362.96 for every dollar of expected revenue over the next 12 months.